Xenon Pharmaceuticals Inc.
XENE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $9 | $18 |
| % Growth | – | -100% | -48.8% | – |
| Cost of Goods Sold | $3 | $168 | $0 | $0 |
| Gross Profit | -$3 | -$168 | $9 | $18 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $210 | $168 | $106 | $75 |
| G&A Expenses | $69 | $47 | $33 | $22 |
| SG&A Expenses | $69 | $47 | $33 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$168 | $0 | $0 |
| Operating Expenses | $277 | $47 | $139 | $97 |
| Operating Income | -$279 | -$214 | -$129 | -$79 |
| % Margin | – | – | -1,368.9% | -428.4% |
| Other Income/Exp. Net | $41 | $31 | $4 | $0 |
| Pre-Tax Income | -$238 | -$183 | -$125 | -$79 |
| Tax Expense | -$4 | -$0 | $0 | -$0 |
| Net Income | -$234 | -$182 | -$125 | -$79 |
| % Margin | – | – | -1,328.9% | -427.8% |
| EPS | -3.01 | -2.73 | -2.06 | -1.77 |
| % Growth | -10.3% | -32.5% | -16.4% | – |
| EPS Diluted | -3.01 | -2.73 | -2.06 | -1.77 |
| Weighted Avg Shares Out | 78 | 67 | 61 | 44 |
| Weighted Avg Shares Out Dil | 78 | 67 | 61 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $42 | $28 | $9 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $4 | $1 | $1 |
| EBITDA | -$236 | -$211 | -$128 | -$78 |
| % Margin | – | – | -1,354% | -423.5% |